Sino Biopharmaceutical Li... (SBMFF)
OTC: SBMFF
· Real-Time Price · USD
0.99
0.00 (0.10%)
At close: Aug 13, 2025, 12:40 PM
0.99
0.00%
After-hours: Aug 13, 2025, 08:00 PM EDT
Sino Biopharmaceutical Balance Sheet Statement
Financials in CNY. Fiscal
year is
January - December.
| Fiscal Year | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Cash & Equivalents | 9.57B | 9.57B | 8.55B | 8.55B | 9.45B | 9.45B | 11.58B | 11.58B | 8.65B | 12.07B | 6.07B | 7.77B | 9.6B | 10.57B | 8.03B | 7.93B |
Short-Term Investments | 5.03B | 5.03B | 4.63B | 4.63B | 4.67B | 1.55B | 4.1B | 160.13M | 8.27B | 4.86B | 9.61B | 7.91B | 6.19B | 569.5M | 2.42B | 2.4B |
Long-Term Investments | 26.34B | 26.34B | 27.41B | 27.41B | 25.18B | 25.18B | 20.16B | 24.26B | 16.96B | 25.23B | 17.83B | 27.43B | 20.51B | 25.17B | 14.76B | 12.37B |
Other Long-Term Assets | 1.04B | 1.04B | 1.27B | 1.27B | 1.23B | 3.78B | 5.46B | 1.87B | 9.5B | 2.71B | 10.87B | 1.67B | 5.96B | 2.42B | 6.39B | 4.49B |
Receivables | 4.97B | 4.97B | 7.3B | 7.3B | 4.6B | 4.6B | 7.11B | 7.11B | 4.64B | 4.64B | 4.95B | 4.95B | 4.29B | 4.29B | 5.06B | 3.25B |
Inventory | 2.37B | 2.37B | 1.84B | 1.84B | 1.99B | 1.99B | 2.02B | 2.02B | 2.33B | 2.33B | 2.14B | 2.14B | 1.94B | 1.94B | 1.73B | 1.81B |
Other Current Assets | 295.61M | 295.61M | 60.97M | 60.97M | 2.52B | 2.52B | 79.89M | 79.89M | 1.58B | 1.58B | 406.92M | 406.92M | 1.25B | 1.25B | 115.41M | 116.79M |
Total Current Assets | 24.69B | 24.69B | 25.22B | 25.22B | 23.81B | 23.81B | 26.98B | 26.98B | 25.93B | 25.93B | 25.2B | 25.2B | 23.5B | 23.5B | 23.81B | 21.79B |
Property-Plant & Equipment | 10.29B | 10.29B | 9.68B | 9.68B | 9.91B | 9.91B | 9.58B | 9.58B | 9.25B | 9.25B | 8.77B | 8.77B | 8.52B | 8.52B | 8.73B | 8.76B |
Goodwill & Intangibles | 3.06B | 3.06B | 3.12B | 3.12B | 2.91B | 928.94M | 2.94B | 2.94B | 1.91B | 940.96M | 1.86B | 1.86B | 1.71B | 939.49M | 1.82B | 1.74B |
Total Long-Term Assets | 40.72B | 40.72B | 41.48B | 41.48B | 39.8B | 39.8B | 38.66B | 38.66B | 38.13B | 38.13B | 39.74B | 39.74B | 37.04B | 37.04B | 32.39B | 27.36B |
Total Assets | 65.41B | 65.41B | 66.7B | 66.7B | 63.6B | 63.6B | 65.64B | 65.64B | 64.06B | 64.06B | 64.93B | 64.93B | 60.54B | 60.54B | 56.21B | 49.15B |
Account Payables | 1.5B | 1.5B | 2.19B | 2.19B | 1.33B | 1.33B | 2.17B | 2.17B | 1.88B | 1.88B | 3.08B | 3.08B | 1.79B | 1.79B | 1.62B | 2.16B |
Deferred Revenue | n/a | n/a | n/a | 10.79M | 10.05B | n/a | 14.19B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Short-Term Debt | 7.68B | 7.68B | 8.5B | 8.5B | 11.27B | 11.27B | 10.48B | 10.48B | 9.8B | 9.8B | 4.07B | 4.07B | 6.66B | 6.66B | 1.82B | 1.21B |
Other Current Liabilities | 7.61B | 10.36B | 11.25B | 11.25B | 3.21B | 3.21B | 14.18B | 14.18B | 2.11B | 2.11B | 9.07B | 9.07B | 1.68B | 1.68B | 8.02B | 6.97B |
Total Current Liabilities | 19.56B | 19.56B | 21.95B | 21.95B | 22.61B | 22.61B | 26.87B | 26.87B | 20.15B | 20.15B | 16.27B | 16.27B | 15.35B | 15.35B | 11.49B | 10.36B |
Long-Term Debt | 2B | 2B | 1.01B | 1.01B | 1.07B | 1.07B | 702.08M | 702.08M | 3.93B | 3.93B | 7.54B | 7.54B | 5.21B | 5.21B | 11.52B | 12.32B |
Other Long-Term Liabilities | 997.36M | 997.36M | 1.47B | 1.47B | 1.46B | 1.46B | 1.29B | 1.29B | 1.71B | 1.71B | 2.03B | 2.03B | 1.94B | 1.94B | 1.8B | 1.36B |
Total Long-Term Liabilities | 3.08B | 3.08B | 2.63B | 2.63B | 2.83B | 2.83B | 2.32B | 2.32B | 5.97B | 5.97B | 9.92B | 9.92B | 7.47B | 7.47B | 13.61B | 13.94B |
Total Liabilities | 22.63B | 22.63B | 24.58B | 24.58B | 25.43B | 25.43B | 29.18B | 29.18B | 26.12B | 26.12B | 26.19B | 26.19B | 22.81B | 22.81B | 25.1B | 24.3B |
Total Debt | 9.78B | 9.78B | 9.68B | 9.51B | 12.58B | 12.64B | 11.55B | 11.52B | 13.98B | 14.06B | 12.02B | 11.97B | 12.12B | 12.19B | 13.65B | 13.79B |
Common Stock | 414.38M | 414.38M | 414.38M | 414.38M | 414.62M | 414.62M | 414.62M | 414.62M | 414.9M | 414.9M | 414.94M | 414.94M | 415.44M | 415.44M | 415.89M | 415.89M |
Retained Earnings | n/a | n/a | 31.85B | 31.85B | 23.65B | 29.34B | 23.35B | 28.64B | 23.07B | 28.36B | 28.54B | 28.54B | 27.21B | 27.21B | 21.3B | n/a |
Comprehensive Income | n/a | 34.52B | -9.73B | -9.73B | -9.95B | -9.95B | -9.88B | -9.88B | -10.08B | -10.08B | -9.85B | -9.85B | -9.23B | -9.23B | -9.36B | 18.72B |
Shareholders Equity | 31.96B | 31.96B | 32.84B | 32.84B | 30.47B | 30.47B | 29.99B | 29.99B | 29.75B | 29.75B | 30.21B | 30.21B | 30.29B | 30.29B | 24.58B | 18.67B |
Total Investments | 31.36B | 31.36B | 32.04B | 32.04B | 25.82B | 26.73B | 24.26B | 24.42B | 25.23B | 30.09B | 27.43B | 35.34B | 25.17B | 25.74B | 17.17B | 14.78B |